Ocular Therapeutix Pre-Tax Profit Margin 2013-2024 | OCUL

Ocular Therapeutix pre-tax profit margin from 2013 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.

Ocular Therapeutix Pre-Tax Profit Margin 2013-2024 | OCUL

Ocular Therapeutix pre-tax profit margin from 2013 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$78.5B
Takeda Pharmaceutical (TAK)$43.1B
Merck (MKKGY)$20.8B
Astellas Pharma (ALPMY)$19.8B
Sandoz Group AG (SDZNY)$19.4B
United Therapeutics (UTHR)$17.9B
Summit Therapeutics (SMMT)$15.3B
Neurocrine Biosciences (NBIX)$12.9B
Shionogi (SGIOY)$12.2B
Catalent (CTLT)$10.8B
Jazz Pharmaceuticals (JAZZ)$7.7B
Madrigal Pharmaceuticals (MDGL)$7.4B
Orion OYJ (ORINY)$6.7B
Corcept Therapeutics (CORT)$6.1B
Ionis Pharmaceuticals (IONS)$6B
Crinetics Pharmaceuticals (CRNX)$4.7B
PTC Therapeutics (PTCT)$3.4B
Dyne Therapeutics (DYN)$2.9B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.9B
Catalyst Pharmaceuticals (CPRX)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.7B
Soleno Therapeutics (SLNO)$2.5B
NewAmsterdam Pharma (NAMS)$2.2B
Recursion Pharmaceuticals (RXRX)$2.1B
Centessa Pharmaceuticals (CNTA)$1.9B
Harrow (HROW)$1.8B
Xencor (XNCR)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.6B
ARS Pharmaceuticals (SPRY)$1.6B
Evotec AG (EVO)$1.6B